Related Experiment Video
Updated: Aug 13, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Chronic graft-versus-host disease
Mitchell E Horwitz1, Keith M Sullivan
1Division of Cellular Therapy, Duke University Medical Center, 2400 Pratt Street DUMC 3961, Durham, NC 27710, USA. mitchell.horwitz@duke.edu
Insights
Chronic graft-versus-host disease (GVHD) affects half of allogeneic stem cell transplant patients. Early treatment improves survival, while severe cases have a poor prognosis, often due to infections.
Area of Science:
- Medicine
- Immunology
- Hematology
Background:
- Chronic graft-versus-host disease (GVHD) is a significant late complication following allogeneic stem cell transplantation.
- It affects approximately 50% of transplant recipients, manifesting at least 100 days post-transplant.
- Increased use of peripheral blood stem cells and older recipient age contribute to higher chronic GVHD incidence.
Purpose of the Study:
- To review the current understanding of chronic GVHD, including its pathophysiology, clinical manifestations, and treatment strategies.
- To highlight the impact of chronic GVHD on patient survival and quality of life.
Main Methods:
- Literature review of chronic GVHD, focusing on incidence, risk factors, affected organs, and treatment outcomes.
- Analysis of standard treatment regimens and their efficacy.
Main Results:
- Chronic GVHD commonly affects the skin, liver, eyes, and mouth, leading to a severely immunocompromised state.
- Standard treatment involves cyclosporine and prednisone, with an alternating day regimen showing improved survival and reduced adverse events.
- Topical therapy is recommended for mild cases.
- Ten-year survival is approximately 80% for mild chronic GVHD but less than 5% for severe cases.
Conclusions:
- Chronic GVHD poses a significant challenge in allogeneic stem cell transplantation, with severe forms having a dismal prognosis.
- Effective management, including early intervention and optimized treatment regimens, is crucial for improving patient outcomes.
- Infectious complications remain a primary cause of mortality in severe chronic GVHD.
Abstract:
Chronic graft versus host disease (GVHD) remains today one of the most vexing late complications of allogeneic stem cell transplantation. Occurring a minimum of 100 days following stem cell transplantation, approximately 50% of patients will experience some degree of chronic GVHD. Host-reactive lymphocytes of donor origin are the cells responsible for the "alloimmune" attack. The increased use of hematopoietic stem cells collected from the peripheral blood instead of bone marrow and the increasing age of stem cell transplant recipients has led to a higher incidence of chronic GVHD. Chronic GVHD most commonly affects the skin, liver, eyes or the mouth, however multiple other sites may also be affected. Chronic GVHD and the medications used to treat it result in a profoundly immunocompromised state. Death due to severe chronic GVHD is usually a consequence of infectious complications. Standard treatment for severe chronic GVHD is a combination of cyclosporine and prednisone. An alternating day regimen of these two agents prolongs survival and reduces drug-related adverse events. Topical therapy to affected areas is preferred for patients with mild disease. The 10-year survival of patients with mild chronic GVHD is approximately 80%, but is less than 5% for patients affected by severe chronic GVHD.
Related Concept Videos
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Chronic Inflammation: Introduction
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cytomegalovirus Disease
Cryptococcal Meningitis
Graves Disease II: Pathophysiology

